Cantor Fitzgerald Downgrades Tvardi Therapeutics (NASDAQ:TVRD) to Neutral

Key Points

• Cantor Fitzgerald downgraded Tvardi Therapeutics (NASDAQ:TVRD) from an "overweight" to a "neutral" rating in a report released on Monday.
• Tvardi Therapeutics stock has experienced a significant decline, trading down approximately 83.6% to $6.83, with a twelve-month low of $5.65.
• The company reported a loss of ($1.00) earnings per share for the last quarter, missing the consensus estimate by $0.49.

Tvardi Therapeutics (NASDAQ:TVRD - Get Free Report) was downgraded by equities researchers at Cantor Fitzgerald from an "overweight" rating to a "neutral" rating in a research report issued to clients and investors on Monday,Briefing.com Automated Import reports.

A number of other analysts have also recently weighed in on the company. Piper Sandler cut Tvardi Therapeutics from an "overweight" rating to a "neutral" rating and decreased their price objective for the stock from $78.00 to $4.00 in a research report on Monday. Barclays started coverage on Tvardi Therapeutics in a research report on Monday. They set an "overweight" rating and a $61.00 price objective for the company. Weiss Ratings reissued a "sell (e)" rating on shares of Tvardi Therapeutics in a research note on Saturday, September 27th. Finally, Raymond James Financial assumed coverage on Tvardi Therapeutics in a research note on Monday, July 14th. They set an "outperform" rating and a $62.00 target price for the company. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $48.80.

Tvardi Therapeutics Trading Down 83.6%

Tvardi Therapeutics stock traded down $34.77 during mid-day trading on Monday, reaching $6.83. 3,061,141 shares of the company were exchanged, compared to its average volume of 47,397. Tvardi Therapeutics has a twelve month low of $5.65 and a twelve month high of $43.65. The stock has a 50-day moving average price of $32.02.

Tvardi Therapeutics (NASDAQ:TVRD - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($1.00) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.49). Tvardi Therapeutics had a negative return on equity of 565.83% and a negative net margin of 678.79%.

Hedge Funds Weigh In On Tvardi Therapeutics

Several hedge funds have recently bought and sold shares of TVRD. Slate Path Capital LP purchased a new position in Tvardi Therapeutics during the second quarter worth $16,427,000. 683 Capital Management LLC purchased a new position in Tvardi Therapeutics during the second quarter worth $4,107,000. Geode Capital Management LLC acquired a new stake in shares of Tvardi Therapeutics during the second quarter worth $2,617,000. Marshall Wace LLP acquired a new stake in shares of Tvardi Therapeutics during the second quarter worth $583,000. Finally, Bank of America Corp DE acquired a new stake in shares of Tvardi Therapeutics during the second quarter worth $399,000. Hedge funds and other institutional investors own 44.66% of the company's stock.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.